Wednesday, July 30, 2014

Valeant’s Cost-Cutting Ethos May Yet Give Wall Street Indigestion by JESSE EISINGER



By JESSE EISINGER


Valeant Pharmaceuticals’ lean business model risks harming its relationship with the Food and Drug Administration and hampering its competitiveness, Jesse Eisinger writes in The Trade.


Published: July 30, 2014 at 4:00AM


from NYT Business Day http://ift.tt/1nIWO9c

via IFTTT








from WordPress http://ift.tt/Xg3mSl
Posted by at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)